Journal Information
Vol. 44. Issue. 3.May - June 2024
Pages 313-458
Vol. 44. Issue. 3.May - June 2024
Pages 313-458
Letter to the Editor
Full text access
Management of refractory pruritus with difelikefalin in a patient on incremental hemodialysis one day a week: Is it safe and effective?
Manejo del prurito refractario con difelikefalina en un paciente en hemodiálisis incremental de un día a la semana. ¿Es seguro y eficaz?
Visits
908
José C. de la Flora,
Corresponding author
jflomer@mde.es

Corresponding author.
, Leonardo Cruzadob, Javier Deirac, Francisco Valgad, Beatriz Sualdeaa, Rocio Zamorae, Miguel Rodelesa
a Servicio de Nefrología, Hospital central de la defensa Gómez Ulla, Madrid, Spain
b Servicio de Nefrología, Hospital General de Elche, Alicante, Spain
c Servicio de Nefrología, Hospital San Pedro de Alcántara, Cáceres, Spain
d Servicio de Nefrología, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canarias, Spain
e Servicio de Nefrología, Hospital Universitario General Villalba, Madrid, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Analytical evolutionary control, haemodialysis parameters and pruritus assessment scales.
Full Text
Dear Editor,

Uraemic pruritus (UP) is one of the symptoms with more effects on the quality of life of the haemodialysis (HD) population. Despite its high prevalence (30–70%), it is not treated adequately.1 Diphelikephaline (DFK) is a peripheral kappa-opioid receptor agonist recently approved for the treatment of UP.2 However, experience of DFK in patients on incremental haemodialysis (iHD) is limited.

We present the case of a 62-year-old woman with a right nephrectomy due to severe hydronephrosis secondary to lithiasis, arterial hypertension and type 2 diabetes mellitus. HD was started due to poor blood pressure control, hyperkalaemia, uraemic symptoms and generalised pruritus, with one weekly session of 240 min and asymmetric cellulose triacetate dialyser-1.9 m2 (ATA®). At the beginning of iHD, there was a clearance of creatinine (ClCr) and urea (KrU) measured by 24-h urine and residual diuresis of 16; 4.70 ml/min/1.73 m2 and 1900 ml respectively.

Due to the persistence of pruritus, dermatological, haematological, hepatic/biliary, neurological, psychiatric and pharmacological causes were ruled out. The patient maintained standard Kt/V adjusted to body surface area greater than 2.3 weekly volumes, high convective volume and residual diuresis with KrU > 4 ml/min. Therefore, it was considered justified not to increase the dialysis dose (Table 1). Initial treatment with moisturisers, dermal emollients, gabapentin and mirtazapine were unsuccessful. The severity of pruritus and the impact on quality of life were evaluated using the WIN-RS and SADS3 questionnaires, presenting 8 points and a moderate degree, respectively. Given the persistence of symptoms, IV DFK was requested (0.5 µg/kg/pos-HD weekly) through the Early Access Program. After 12 weeks of treatment, pruritus was reduced to 4 points and a mild degree on the WIN-RS and SADS scales, respectively (Table 1). The patient did not have adverse effects with this drug during follow-up.

Table 1.

Analytical evolutionary control, haemodialysis parameters and pruritus assessment scales.

  Start of haemodialysis  Baseline  Week 4  Week 8  Week 12 
Hb (g/dl)  11.5  12  11.5  11.2  11.3 
Na+ (mmol/l)  139  139  136  137  140 
K+ (mmol/l)  5.9  5.2  4.9  4.8  4.7 
Uric acid (mg/dl)  8.8  7.8  7.4  7.2  6.8 
Serum albumin (mg/dl)  2.8  3.2  3.2  3.3  3.3 
Serum glucose (mg/dl)  148  154  154  150  157 
HbA1c (%)  6.5  6.2  N/A  N/A  6.0 
Weight (kg)  70.5  69.5  68.4  67  67 
Phosphorus (mg/dl)  5.7  4.9  4.5  4.5  4.7 
Calcium (mg/dl)  8.9  8.9  8.7  8.8 
PTH (pg/ml)  189  180  210  212  288 
25-Hydroxy-vitamin D (ng/ml)  17  14.5  20.5  26  28 
Direct bilirubin (mg/dl)  0.8  0.9  0.9  0.8 
WI-NRS 
SADS  Moderate  Moderate  Moderate  Mild  Mild 
Serum creatinine (mg/dl)  4.5  4.35  4.21  4.06  4.5 
Serum urea (mg/dl)  121  128  123  129  126 
CKD-EPI (ml/min)  10  11  11  12  10 
Residual diuresis (ml/24 h)  1900  1800  2200  2500  2200 
KrU (ml/min)  4.7  6.2  6.3  6.5  6.3 
ClCr (ml/min/1.73 m216  16  17  20  19 
IFG (ml/min/1.73 m210.3  10.3  10.75  12.75  11.75 
Bicarbonate (mmol/l)  15  18.8  20.3  24.3  20 
ACR (mg/g)  3300  3300  3100  2800  2300 
VB (l)  N/A  80  82  85  86 
Vinf-OL-HDF (l)  N/A  24  26.4  26  25.3 
Kt/v (L)  N/A  1.45  1.55  1.55  1.55 
BSA-normalised std Kt/V (l)  N/A  5.24%  5.49  5,87  5,48. 
EKRU Casino (ml/min)  N/A  18.1  18.6  19.4  18 
KT (l)  N/A  53  56.7  54  56 
IDWG (kg)  N/A  1.2  0.9  0.8 

ACR: albumin/creatinine ratio; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; CrCl: 24-h urinary Cr clearance; IDWG: interdialytic weight gain; Hb: haemoglobin; Hb1Ac: glycated haemoglobin; HD: haemodialysis; GFR: glomerular filtration rate; K +: plasma potassium; KrU: residual renal urea clearance; KT: efficacy of dialysis treatment; N/A: not assigned; na +: plasma sodium; PTH: paratohomorna; SADS: Patient Assessed Severity of Illness Scale; BSA-normalised std Kt/V: standard Kt/V normalised to body surface area; Vinf-OL-HDF: infusion volume in online hemodiafiltration; VB: dialysed blood volume; WI-NRS: worst itch numeric rating scale.

The management of UP continues to be complex due to its multifactorial origin. After ruling out secondary causes, different topical and systemic pharmacological treatments were proposed, with gabapentin being the only drug with a proven effect on UP.1 Furthermore, it has been classically associated with low-flow dialysis and blood levels. Kt/V < 1.5 l.4 There was a hypothesis that those patients who maintained residual renal function on peritoneal dialysis were associated with a lower incidence of UP due to the elimination of larger molecules,5 but recent studies have not found such a relationship.6 In addition, within HD techniques, high-flow HD, online haemodiafiltration and adsorptive HD are associated with improvement in PU symptoms,7 as these techniques are considered to improve the purification of uraemic toxins and the inflammatory state. However, to date, none of these dialysis treatments have been shown to be effective in preventing UP. Only kidney transplantation significantly improves the symptoms of UP.7

In a recent clinical trial, 378 HD patients with moderate-severe pruritus were randomised 1:1 to receive DFK and placebo, 3 times a week post-HD, for 12 weeks. DFK demonstrated rapid efficacy with a significant reduction in pruritus by at least 3 points on the WIN-RS itch scale compared to placebo (51.9% vs. 30.9%), providing an improvement in quality of life.8 However, studies conducted in the HD population only include patients with the conventional 3-day-a-week regimen, without including iHD patients.

For the first time, our case describes the efficacy and safety of DFK in the management of pruritus in a patient on iHD with one session per week. In our centre, in incident patients, the frequency of HD doses is adjusted based on KrU, following the criteria collected in the DIPPI9 study and the recommendations of the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) of 2015.10 During follow-up, our patient maintained unchanged diuresis, CrCl and KrU, with correct HD efficacy values, without the need to increase the frequency of the dialysis dose. The new document from the Spanish Society of Nephrology (SEN) on the management of pruritus in HD11 recommends the prescription of DKF for refractory cases.

According to our experience, in patients with adequate renal and dialytic clearance who present refractory pruritus, the use of DFK is useful and safe, and avoids increasing the dialysis dose. This allows us to preserve the quality of life of patients and reduce the cost associated with a greater number of weekly sessions.12

Ethical responsibilities

The study complied with the principles set out in the Declaration of Helsinki. The authors declare they received the informed consent of the subject studied, and respect the patient's right to privacy. No experiments were performed on humans or animals for this study.

Conflicts of interest

The author has no conflicts of interest or financial support to declare.

References
[1]
C. Santos-Alonso, M. Maldonado Martín, R. Sánchez Villanueva, L. Álvarez García, M.A. Vaca Gallardo, M.A. Bajo Rubio, et al.
Pruritus in dialysis patients. Review and new perspectives.
Nefrologia [Internet], 42 (2022 Jan 1), pp. 15-21
[2]
Kapruvia | European Medicines Agency [Internet]. [Accessed 16 June 2023]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kapruvia.
[3]
V.S. Mathur, J. Lindberg, M. Germain, G. Block, J. Tumlin, M. Smith, et al.
A longi-tudinal study of uremic pruritus in hemodialysis patients.
Clin J Am Soc Nephrol [Internet], 5 (2010 Aug 1), pp. 1410-1419
[4]
M.J. Ko, H.Y. Wu, H.Y. Chen, Y.L. Chiu, S.P. Hsu, M.F. Pai, et al.
Uremic Pruritus, Dialysis Adequacy, and Metabolic Profiles in Hemodialysis Patients: A Prospec-tive 5-Year Cohort Study.
PLoS One [Internet], 8 (2013),
[5]
H.Y. Wu, Y Sen Peng, H.Y. Chen, W.C. Tsai, J.Y. Yang, S.P. Hsu, et al.
A Compari-son of Uremic Pruritus in Patients Receiving Peritoneal Dialysis and Hemodialy-sis.
Medicine [Internet], 95 (2016),
[6]
J.W. Min, S.H. Kim, Y.O. Kim, D.C. Jin, H.C. Song, E.J. Choi, et al.
Comparison of uremic pruritus between patients undergoing hemodialysis and peritoneal dialysis.
Kidney Res Clin Pract [Internet], 35 (2016), pp. 107
[7]
P. Molina, R. Ojeda, A. Blanco, G. Alcalde, M. Prieto-Velasco, N. Aresté, et al.
Eti-opatogenia del prurito asociado a la enfermedad renal crónica: recomponiendo las piezas del puzle.
[8]
S. Fishbane, A. Jamal, C. Munera, W. Wen, F. Menzaghi.
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
[9]
M.A. Suárez, E. García-Cabrera, A. Gascón, F. López, E. Torregrosa, G.E. García, et al.
Justificación y diseño de DiPPI: un ensayo controlado aleatorizado para evalu-ar la seguridad y la efectividad de la hemodiálisis progresiva en pacientes inci-dentes.
Nefrología, 38 (2018), pp. 630-638
[10]
M. Rocco, J.T. Daugirdas, T.A. Depner, J. Inrig, R. Mehrotra, M.V. Rocco, et al.
KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update.
American Journal of Kidney Diseases [Internet], 66 (2015), pp. 884-930
[11]
J.M. Buades, I. Figueras-Nart, M. Goicoechea, R.J. Sánchez Villanueva, E. Serra-Baldrich.
Documento de información y consenso para el manejo diagnóstico y terapéutico del prurito asociado a la enfermedad renal crónica en pacientes en hemodiálisis en España.
[12]
E. Caton, S. Sharma, E. Vilar, K. Farrington.
Impact of incremental initiation of haemodialysis on mortality: a systematic review and meta-analysis.
Nephrol Dial Transplant [Internet], 38 (2023 Feb 1), pp. 435-446
Copyright © 2023. Sociedad Española de Nefrología
Download PDF
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?